Structural insights into the unique activation mechanisms of receptor tyrosine kinases
受体酪氨酸激酶独特激活机制的结构见解
基本信息
- 批准号:10434122
- 负责人:
- 金额:$ 40.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAgrinBindingBiochemicalBiological AssayBiological ProcessCell Surface ReceptorsCell membraneCell physiologyCell surfaceCellsComplexCryoelectron MicroscopyDataDevelopmentDimerizationEnvironmentExhibitsFamilyGoalsHGF geneHeparinIn VitroInflammationKDR geneLaboratoriesLearningLengthLigand BindingLigandsLinkLipidsLiposomesMaintenanceMalignant NeoplasmsMembraneMembrane LipidsModelingMolecularMolecular ConformationMuscleMuscle CellsMutagenesisNeuromuscular JunctionNormal CellPDGFRB genePhosphatidylserinesPhosphotransferasesPhysiologicalPlayProtein IsoformsProtein Tyrosine KinaseProteinsProtomerReceptor ActivationReceptor CellReceptor Protein-Tyrosine KinasesRegulationResolutionRoleSamplingSignal TransductionStructureTAC1 geneTertiary Protein Structureadaptive immunityantagonistbasecell motilitycrosslinkdimerextracellularhuman diseaseimprovedinsightmembernanodiskreceptorreconstitutionrecruit
项目摘要
Receptor tyrosine kinases (RTKs) play key roles in regulating normal cellular processes and are linked to many
human diseases. Each RTK protomer contains an extracellular region that binds activating ligands, a single
transmembrane helix, and an intracellular region that contains the kinase domain necessary for intracellular
signaling. For many RTKs, their cognate ligands form stable homodimers, and the binding of dimeric ligand to
the extracellular region of RTK drives receptor dimerization, which then brings two intracellular kinases in close
proximity, enabling their autophosphorylation. The phosphorylated kinases can further recruit effector proteins,
and thereby triggering downstream signaling cascade. This “ligand-induced-dimerization” is the long-standing
model for the activation of RTKs, and has been well characterized by extensive structural and functional
studies. Nevertheless, it has been suggested that several members in RTK family use unique activation
mechanisms. For instance, the MuSK receptor alone cannot directly bind to and be activated by its ligand
Agrin, but requiring assistance of the co-receptor Lrp4 on the muscle cell surface for activation. In addition, the
activation of TAM receptor requires not only the binding of its ligands, but also the involvement of
phosphatidylserine lipid (PtdSer) from plasma membrane. Furthermore, our preliminary structure results
showed that, different to all other RTKs, one HGF molecular can simultaneously engages two c-MET receptors
by utilizing two distinct interfaces; therefore, a single HGF is sufficient for the activation of c-MET receptor,
which represents another paradigm in activation mechanisms of RTK. The goal of this project is to study the
structures and functions of several special RTKs, including MuSK, TAM and c-MET receptors, whose
activation mechanism are still poorly understood. Solving the high-resolution structures of different unique
members of RTK family in the ligand-bound active state will explain the specific features that differentiate these
receptors from other RTKs, and reveal the common mechanism and diversification in the activation of RTK.
Aim 1 will be focused on the functional and structural analyses of MuSK receptor complex. This study will
reveal the detailed binding mode between MuSK, Lrp4 and Agrin, and explain why co-receptor Lrp4 is critical
for the activation of MuSK. Aim 2 will be focused on biochemical and structural analyses of TAM receptor in the
membrane associated functional state. The result from this study will allow us to explain the functional
importance of PtdSer in TAM activation. Aim 3 will be focused on the structural determination of c-MET
receptor in the HGF bound active state to understand why single HGF molecular is sufficient for c-MET
activation.
受体酪氨酸激酶(RTK)在调节正常细胞过程中起关键作用,并与许多细胞因子相关。
人类疾病。每个RTK原聚体含有结合活化配体的细胞外区域,
跨膜螺旋,和含有细胞内激酶结构域所必需的细胞内区域,
信号对于许多RTK,它们的同源配体形成稳定的同源二聚体,并且二聚体配体与RTK的结合不稳定。
RTK的胞外区驱动受体二聚化,然后使两种胞内激酶紧密结合
接近,使其自身磷酸化。磷酸化激酶可以进一步募集效应蛋白,
从而触发下游信号级联。这种“配体诱导的二聚化”是长期存在的
RTKs的激活模型,并已充分表征了广泛的结构和功能
问题研究然而,有人建议RTK家族中的几个成员使用唯一激活
机制等例如,单独的MuSK受体不能直接结合其配体并被其激活,
聚集蛋白,但需要肌肉细胞表面上的辅助受体Lrp 4的辅助来激活。此外该
TAM受体的激活不仅需要其配体的结合,而且还需要
磷脂酰丝氨酸脂质(PtdSer)。此外,我们的初步结构结果
表明,与所有其他RTK不同,一个HGF分子可以同时接合两个c-MET受体
通过利用两个不同的界面;因此,单一HGF足以激活c-MET受体,
这代表了RTK激活机制的另一种范例。该项目的目标是研究
几种特殊的RTKs,包括MuSK,TAM和c-MET受体的结构和功能,
激活机制仍然知之甚少。解决不同独特的高分辨率结构
配体结合活性状态的RTK家族成员将解释区分这些的具体特征。
受体之间的相互作用,揭示了RTK激活的共同机制和多样性。
目标1将重点关注MuSK受体复合物的功能和结构分析。本研究将
揭示MuSK、Lrp 4和聚集蛋白之间的详细结合模式,并解释为什么辅助受体Lrp 4是关键的
用于激活MuSK。目的二是对TAM受体进行生物化学和结构分析,
膜相关功能状态。这项研究的结果将使我们能够解释功能性
PtdSer在TAM活化中重要性。目标3将集中于c-MET的结构测定
受体处于HGF结合活性状态,以了解为什么单个HGF分子足以用于c-MET
activation.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiaochen Bai其他文献
Xiaochen Bai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiaochen Bai', 18)}}的其他基金
Novel regulatory mechanisms and agonists of STING
STING 的新颖调控机制和激动剂
- 批准号:
10655761 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
Structural insights into the unique activation mechanisms of receptor tyrosine kinases
受体酪氨酸激酶独特激活机制的结构见解
- 批准号:
10273083 - 财政年份:2021
- 资助金额:
$ 40.63万 - 项目类别:
Structural insights into the unique activation mechanisms of receptor tyrosine kinases
受体酪氨酸激酶独特激活机制的结构见解
- 批准号:
10600031 - 财政年份:2021
- 资助金额:
$ 40.63万 - 项目类别:
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State
配体活性状态下全长胰岛素受体 (IR) 和 1 型胰岛素样生长因子受体 (IGF1R) 的结构和功能分析
- 批准号:
10350608 - 财政年份:2020
- 资助金额:
$ 40.63万 - 项目类别:
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State
配体活性状态下全长胰岛素受体 (IR) 和 1 型胰岛素样生长因子受体 (IGF1R) 的结构和功能分析
- 批准号:
10386663 - 财政年份:2020
- 资助金额:
$ 40.63万 - 项目类别:
Structural and Functional Analyses of the Full-length Insulin Receptor (IR) and Type 1 Insulin-like Growth Factor Receptor (IGF1R) in the Liganded Active State
配体活性状态下全长胰岛素受体 (IR) 和 1 型胰岛素样生长因子受体 (IGF1R) 的结构和功能分析
- 批准号:
10574524 - 财政年份:2020
- 资助金额:
$ 40.63万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 40.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 40.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 40.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)